Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 8033-8040

  Kindler, Hedy L ^a   Friberg, Gregory ^b   Singh, Deepti A ^b   Locker, Gershon ^b   Nattam, Sreenivasa ^b   Kozloff, Mark ^b   Taber, David A ^b   Karrison, Theodore ^b   Dachman, Abraham ^b   Stadler, Walter M ^b   Vokes, Everett E ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; GEMCITABINE; MONOCLONAL ANTIBODY; VASCULOTROPIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTIC SYNDROME; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; SIDE EFFECT; STOMACH PERFORATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOCARCINOMA; BLOOD; DISEASE COURSE; DISEASE FREE SURVIVAL; LIVER TUMOR; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PANCREAS TUMOR; PATHOLOGY; PERITONEUM TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 32944478346     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.9661     Document Type: Article

References (40)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer Statistics, 2004. CA Cancer J Clin 54:8-29, 2004
2. Burris HA, Moore MJ, Andersen J III, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
3. Berlin JD, Catalano P, Thomas JP, et al: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275, 2002
4. Richards DA, Kindler HL, Oettle H, et al: A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22, 2004 (abstr 4007)
5. Rocha Lima CM, Green MR, Rotche R, et al: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776-3783, 2004
6. Heinemann V, Quietzsch D, Gieseler F, et al: A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 22:250, 2003 (abstr 1003)
7. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23(15):3509-3516, 2005
8. Korc M: Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2:8, 2003
9. Itakura J, Ishiwata T, Shen B, et al: Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 85:27-34, 2000 10. Luo J, Guo P, Matsuda K, et al: Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer 92:361-369, 2001
10. von Marschall Z, Cramer T, Hocker M, et al: De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop. Gastroenterology 119:1358-1372, 2000
11. Baker CH, Solorzano CC, Fidler IJ: Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 62:1996-2003, 2002
12. Solorzano CC, Baker CH, Bruns CJ, et al: Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase. Cancer Biother Radiopharm 16:359-370, 2001
13. Bockhorn M, Tsuzuki Y, Xu L, et al: Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res 9:4221-4226, 2003
14. Tsuzuki Y, Mouta Carreira C, Bockhorn M, et al: Pancreas microenvironment promotes VEGF expression and tumor growth: Novel window models for pancreatic tumor angiogenesis and microcirculation. Lab Invest 81:1439-1451, 2001
15. Bruns CJ, Shrader M, Harbison MT, et al: Effect of the vascular endothelial growth factor receptor-2 antibody DC-101 plus gemcitabine on growth, metastasis, and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102:101-108, 2002
16. Karayiannakis AJ, Bolanaki H, Syrigos KN, et al: Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 194:119-124, 2003
17. Ikeda N, Adachi M, Taki T, et al: Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79:1553-1563, 1999
18. Itakura J, Ishiwata T, Friess H, et al: Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 3:1309-1316, 1997
19. Knoll MR, Rudnitzki D, Sturm J, et al: Correlation of postoperative survival and angiogenic growth factors in pancreatic carcinoma. Hepatogastroenterology 48:1162-1165, 2001
20. Niedergethmann M, Hildenbrand R, Wostbrock B, et al: High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25:122-129, 2002
21. Seo Y, Baba H, Fukuda T, et al: High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88:2239-2245, 2000
22. Ellis LM, Takahashi Y, Fenoglio CJ, et al: Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 34:337-340, 1998
23. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
24. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
25. Giantonio BJ, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group study E3200. Proc Am Soc Clin Oncol, 2005 (abstr 2)
26. Salven P, Manpaa H, Orpana A, et al: Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 3:647-651, 1997
27. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
28. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
29. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 38:29-41, 1982
30. Goldman Al: Issues in designing sequential stopping rules for monitoring side effects in clinical trials. Control Clin Trials 8:327-337, 1987
31. Kulke MH: Advanced pancreatic cancer: Is there a role for combination therapy? Expert Rev Anticancer Ther 3:729-739, 2003
32. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29-34, 1994
33. Khorana AA, Fine RL: Pancreatic cancer and thromboembolic disease. Lancet Oncol 5:655-663, 2004
34. Sorensen HT, Mellemkjaer L, Olsen JH, et al: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850, 2000
35. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
36. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004
37. Sandler AB, Gray R, Brahmer J, et al: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (CP) with or without bevacizumab (NSC# 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599. Proc Am Soc Clin Oncol, 2005 (abstr 4)
38. Salven P, Orpana A, Joensuu H: Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 5:487-491, 1999
39. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
40. [Erratum: Nat Med 10:649, 2004]